Myocardial Infarction News and Research

RSS

Neighborhood SES and leisure-time physical activity after myocardial infarction

Engaging in physical activity after a heart attack is known to increase the odds of survival. In a study published in the September issue of the American Journal of Preventive Medicine, researchers from the Israel Study Group on First Acute Myocardial Infarction found that myocardial infarction survivors who lived in low socioeconomic status neighborhoods engaged in lower levels of leisure-time physical activity compared to survivors from wealthier neighborhoods.

2 Aug 2011

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.

1 Aug 2011

Anthera reports increase in second quarter total operating expenses to $22.7 million

Anthera Pharmaceuticals, Inc., today announced financial results and business highlights for the quarter ended June 30, 2011.

29 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.

26 Jul 2011

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.

26 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

Study: Married people seek medical care sooner for chest pain

Men who are married or in common-law relationships seek medical care sooner for heart attacks compared with single, divorced or widowed men, found a new study in CMAJ.

19 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

Chronic self-reported NSAID use associated with increased risk of adverse events in hypertensive patients with CAD

A study published in the July issue of The American Journal of Medicine, reports that among hypertensive patients with coronary artery disease, chronic self-reported use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of adverse events during long-term follow-up. Long-term NSAID use is common for treatment of chronic pain.

13 Jul 2011

Enrollment complete in Boston Scientific's Adapt Monorail Carotid Stent System trial

Boston Scientific Corporation has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its Adapt Monorail Carotid Stent System in combination with its FilterWire EZ Embolic Protection System for treatment of carotid artery disease in patients at high risk for carotid surgery.

13 Jul 2011

Coronary artery disease is a predictor for new-onset atrial fibrillation after heart attack

Results from a case control study show that coronary artery disease affecting the atrial branches is an independent predictor for new-onset atrial fibrillation (AF) after acute myocardial infarction (MI), or heart attack.

12 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Autologous adult stem cells reduce frequency of angina episodes

New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options).

From Baxter International Inc. 8 Jul 2011

Critical access hospitals provide lower quality of care

In an analysis of data from more than 4,500 hospitals that serve Medicare beneficiaries, critical access hospitals had fewer clinical capabilities, worse measured processes of care and higher rates of death for patients with heart attack, congestive heart failure or pneumonia, compared to non-CAHs, according to a study in the July 6 issue of JAMA.

6 Jul 2011

Study: More PCIs classified as appropriate for acute indications in the U.S.

In an examination of the appropriateness of the widespread use of percutaneous coronary interventions (PCIs), researchers found that of more than 500,000 PCIs included in the study, nearly all for acute indications were classified as appropriate, whereas only about half of PCIs performed for nonacute indications could be classified as appropriate, according to a study in the July 6 issue of JAMA.

6 Jul 2011

Research roundup: Hospital care in U.S. territories lags; health spending unevenly distributed

This study examines the quality of hospital care in the U.S. territories -- Puerto Rico, Guam, the Northern Mariana Island, and the U.S. Virgin Islands -- and compares it to care in the states.

2 Jul 2011

Lantheus commences flurpiridaz F 18 PET MPI Phase 3 trial for detection of coronary artery disease

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of the first of two Phase 3 clinical trials to assess myocardial perfusion using Positron Emission Tomography (PET) imaging with flurpiridaz F 18 in patients with suspected or known coronary artery disease (CAD).

1 Jul 2011

Fast track protocol reduces hospital costs and infections in total hip replacement surgery

Generally healthy patients who undergo total hip replacement (THR) can be fast tracked to be discharged in two days compared with the standard three to six days, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study could help cut down on hospital-acquired infections, reduce hospital costs and improve patient satisfaction.

1 Jul 2011

Genetic variation associated with increased risk of sudden cardiac arrest

A study by a global consortium of physician-scientists has identified a genetic variation that may predispose people to double the risk of having a sudden cardiac arrest, a disorder that gives little warning and is fatal in about 95 percent of cases.

1 Jul 2011

Myocardial Infarction News and Research

Neighborhood SES and leisure-time physical activity after myocardial infarction

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Anthera reports increase in second quarter total operating expenses to $22.7 million

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

Hormone therapy may be hazardous in men with pre-existing heart conditions

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

Study: Married people seek medical care sooner for chest pain

NeoStem to acquire Amorcyte

Chronic self-reported NSAID use associated with increased risk of adverse events in hypertensive patients with CAD

Enrollment complete in Boston Scientific's Adapt Monorail Carotid Stent System trial

Coronary artery disease is a predictor for new-onset atrial fibrillation after heart attack

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Autologous adult stem cells reduce frequency of angina episodes

Critical access hospitals provide lower quality of care

Study: More PCIs classified as appropriate for acute indications in the U.S.

Research roundup: Hospital care in U.S. territories lags; health spending unevenly distributed

Lantheus commences flurpiridaz F 18 PET MPI Phase 3 trial for detection of coronary artery disease

Fast track protocol reduces hospital costs and infections in total hip replacement surgery

Genetic variation associated with increased risk of sudden cardiac arrest

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News